PExA receives order from Norway’s national occupational health institute STAMI
PExA AB has received an order for a research instrument from the Norwegian National Institute of Occupational Health (STAMI) for studying respiratory diseases through analysis of exhaled particles. Delivery is expected during the first half of 2026.
The instrument will initially be used in a research study focusing on occupational exposure and biological effects in the airways of workers in the slaughterhouse industry. The study will include approximately 150 individuals and will be conducted at seven different slaughterhouses in Norway.
Sampling will be performed in mobile field settings. PExA’s non-invasive technology enables collection of particles from the distal small airways directly at the workplace, after which the samples will be analysed using proteomic methods.
- STAMI’s decision to use PExA in this type of extensive field study is very encouraging. The fact that our technology will now be used by another national occupational health authority strengthens our position within occupational health. The order is further proof that our instrument works well also in mobile research environments, says Tomas Gustafsson, CEO of PExA AB.
STAMI is Norway’s national institute for occupational health research and works to identify and prevent health risks in working life.
- The PExA technology enables us to collect biological material from the small airways in a non-invasive way, also under field conditions. This provides new opportunities in occupational health research, says Raymond Olsen, Senior Researcher at STAMI.
PExA technology is currently used by research groups in Europe, the United States, South Africa and Australia across several research areas. These include occupational exposure studies, biomarker research related to lung diseases such as lung cancer and pulmonary fibrosis, ongoing studies investigating pulmonary embolism, as well as pharmacokinetic and pharmacodynamic research including vaccine studies.
PExA already has several users within occupational health research, including research groups in Örebro, Gothenburg and Aarhus (Denmark) as well as national occupational health authorities such as NIOSH in the United States and BAuA in Germany.
For further information, please contact:
Tomas Gustafsson, CEO, info@pexa.se
About PExA AB:
PExA AB PExA AB (556956-9246) has developed the PExA 2.1, a patented research instrument that helps researchers intelligently collect biological samples from the smallest airways through a simple exhalation maneuver. PExA’s technology is currently used by prominent research groups in several different countries and research with the instrument has resulted in approximately 50 scientific publications, which serve as reference material for PExA’s method. The company’s long-term goal is to market and sell diagnostic instruments for popular diseases (e.g. lung cancer and COPD) to be used globally for diagnosis or general screening at facilities where care is offered. The company intends at the time it is relevant to sell to clinics to have developed more patient-friendly, flexible and commercial products, which means that PExA addresses a significantly wider market, which today includes several million patients globally.
PExA’s B share is listed on the Spotlight Stock Market.